Search Results

• • 19 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia

  Authors:Jennifer N. Wu, Luca Pinello, Elinor Yissachar, Jonathan W. Wischhusen, Guo-Cheng Yuan, and Charles W. M. RobertsFrom:Epigenetics & Chromatin (Vol. 8, Issue 1) Peer-Reviewed

  Dec. 2, 20159,801 words Article 1530LBackground Precise nucleosome positioning is an increasingly recognized feature of promoters and enhancers, reflecting complex contributions of DNA sequence, nucleosome positioning, histone modification and...

• Cancer-fighting Smurf

  Authors:Xi Wang and Charles W M. RobertsFrom:Nature Medicine (Vol. 18, Issue 2) Peer-Reviewed

  Feb. 20121,634 words Report 1540LA newly identified role for SMAD specific E3 ubiquitin protein ligase 2 (Smurf2) in the regulation of histone ubiquitination uncovers a broad tumor suppressor activity that helps to maintain genomic stability in mice. A...

• ARID1B is a specific vulnerability in ARID1A-mutant cancers

  Authors:Katherine C. Helming, Xiaofeng Wang, Boris G. Wilson, Francisca Vazquez, Jeffrey R. Haswell, Haley E. Manchester, et al.From:Nature Medicine (Vol. 20, Issue 3) Peer-Reviewed

  Mar. 20143,147 words Report 1510LRecent studies have revealed that ARID1A, encoding AT-rich interactive domain 1A (SWI-like), is frequently mutated across a variety of human cancers and also has bona fide tumor suppressor properties. Consequently,...

• Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice

  Authors:Charles W. M. Roberts, Shelly A. Galusha, Mairin E. McMenamin, Christopher D. M. Fletcher, and Stuart H. OrkinFrom:Proceedings of the National Academy of Sciences of the United States (Vol. 97, Issue 25) Peer-Reviewed

  Dec. 5, 2000201 words Article

   Abstract Only

• Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

  Authors:Giannicola Genovese, Alessandro Carugo, James Tepper, Frederick Scott Robinson, Liren Li, Maria Svelto, et al.From:Nature (Vol. 542, Issue 7641) Peer-Reviewed

  Feb. 16, 201714,340 words Report 1540LAuthor(s): Giannicola Genovese (corresponding author) [1]; Alessandro Carugo [1, 2, 3]; James Tepper [1]; Frederick Scott Robinson [1, 2]; Liren Li [1, 4]; Maria Svelto [1, 5]; Luigi Nezi [1]; Denise Corti [1]; Rosalba...

• Metagene projection for cross-platform, cross-species characterization of global transcriptional states

  Authors:Pablo Tamayo, Daniel Scanfeld, Benjamin L. Ebert, Michael A. Gillette, Charles W.M. Roberts, and Jill P. MesirovFrom:Proceedings of the National Academy of Sciences of the United States (Vol. 104, Issue 14) Peer-Reviewed

  Apr. 3, 2007161 words Author abstract

   Abstract Only

• Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia

  Authors:Masahiko Hatano, Charles W.M. Roberts, Mark Minden, William M. Crist, and Stanley J. KorsmeyerFrom:Science (Vol. 253, Issue 5015) Peer-Reviewed

  July 5, 19912,070 words Article SPECIFIC INTERCHROMOSOMAL TRANSLOCATIONS are repeatedly found in distinct types of malignancies [1]. Chromosomal translocations found in lymphoid neoplasms provide the opportunity to identify new putative...

• Hox11 controls the genesis of the spleen

  Authors:Charles W.M. Roberts, John R. Shutter, and Stanley J. KorsmeyerFrom:Nature (Vol. 368, Issue 6473) Peer-Reviewed

  Apr. 21, 199440 words Article

   Citation Only

• CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

  Authors:Liying Chen, Gabriela Alexe, Neekesh V. Dharia, Linda Ross, Amanda Balboni Iniguez, Amy Saur Conway, et al.From:Journal of Clinical Investigation (Vol. 128, Issue 1) Peer-Reviewed

  Jan. 201810,086 words Article 1440LPharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with...

• A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

  Authors:Ryan S. Lee, Chip Stewart, Scott L. Carter, Lauren Ambrogio, Kristian Cibulskis, Carrie Sougnez, et al.From:Journal of Clinical Investigation (Vol. 122, Issue 8) Peer-Reviewed

  Aug. 20123,229 words Article 1420LCancer is principally considered a genetic disease, and numerous mutations are thought essential to drive its growth. However, the existence of genomically stable cancers and the emergence of mutations in genes that...

• Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters.

  Authors:Michael Y. Tolstorukov, Courtney G. Sansam, Ping Lu, Edward C. Koellhoffer, Katherine C. Helming, Burak H. Alver, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 110, Issue 25) Peer-Reviewed

  June 18, 2013164 words Report, Author abstr...

   Abstract Only

• Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation

  Authors:Michael S. Isakoff, Courtney G. Sansam, Pablo Tamayo, Aravind Subramanian, Julia A. Evans, Christine M. Fillmore, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 102, Issue 49) Peer-Reviewed

  Dec. 6, 2005197 words Author abstract

   Abstract Only

• Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

  Authors:Gregory R. Hoffman, Rami Rahal, Frank Buxton, Kay Xiang, Gregory McAllister, Elizabeth Frias, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 111, Issue 8) Peer-Reviewed

  Feb. 25, 2014214 words Report, Author abstr...

   Abstract Only

• Targeting EZH2 in cancer

  Authors:Kimberly H. Kim and Charles W.M. RobertsFrom:Nature Medicine (Vol. 22, Issue 2) Peer-Reviewed

  Feb. 20166,770 words Report 1440LRecent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is...

• SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

  Authors:Kimberly H. Kim, Woojin Kim, Thomas P. Howard, Francisca Vazquez, Aviad Tsherniak, Jennifer N. Wu, et al.From:Nature Medicine (Vol. 21, Issue 12) Peer-Reviewed

  Dec. 20154,558 words Report 1470LHuman cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex...

• TCR-dependent transformation of mature memory phenotype T cells in mice.

  Authors:Xi Wang, Miriam B.F. Werneck, Boris G. Wilson, Hye-Jung Kim, Michael J. Kluk, Christopher S. Thom, et al.From:Journal of Clinical Investigation (Vol. 121, Issue 10) Peer-Reviewed

  Oct. 20118,115 words Report 1450LA fundamental goal in cancer research is the identification of the cell types and signaling pathways capable of initiating and sustaining tumor growth, as this has the potential to reveal therapeutic targets. Stem and...

• Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.

  Authors:Jie Yin, Jianmei W. Leavenworth, Yang Li, Qi Luo, Huafeng Xie, Xinhua Liu, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 112, Issue 52) Peer-Reviewed

  Dec. 29, 20156,261 words Report 1490L

   Abstract Only

• Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway

  Authors:Zainab Jagani, E. Lorena Mora-Blanco, Courtney G. Sansam, Elizabeth S. McKenna, Boris Wilson, Dongshu Chen, et al.From:Nature Medicine (Vol. 16, Issue 12) Peer-Reviewed

  Dec. 20104,077 words Report 1410LAberrant activation of the Hedgehog (Hh) pathway can drive tumorigenesis (1). To investigate the mechanism by which glioma-associated oncogene family zinc finger-1 (GLI1), a crucial effector of Hh signaling (2),...

• Toward understanding and exploiting tumor heterogeneity

  Authors:Ash A. Alizadeh, Victoria Aranda, Alberto Bardelli, Cedric Blanpain, Christoph Bock, Christine Borowski, et al.From:Nature Medicine (Vol. 21, Issue 8) Peer-Reviewed

  Aug. 20157,429 words Author abstract, Rep... 1550LThe extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise...